Image-guided moderately hypofractionated proton beam therapy for localized prostate cancer: 5-year outcomes of a phase II trial
Clicks: 35
ID: 322594
2026
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
Emerging Content
10.2
/100
35 views
7 readers
AI Quality Assessment
Not analyzed
Readership in this journal
EmergingRanked #11 of 24 articles by views in journal of radiation research
Most read
Least read
Bar heights use a square-root scale.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
The purpose of the present study is to confirm the efficacy and feasibility of moderately hypofractionated proton beam therapy (PBT) at a total dose of 63 Gy relative biological effectiveness (RBE) in 21 fractions for prostate cancer. This phase II clinical trial (PPS-002: UMIN 000017679) enrolled 125 men with histologically confirmed prostate cancer (cT1c-3aN0M0). The primary endpoint was grade ≥2 late gastrointestinal (GI) toxicities. Secondary endpoints included biochemical recurrence rates, clinical recurrence rates, overall survival (OS) and acute toxicities and late genitourinary (GU) toxicities. With a median follow-up period of 71.0 months (IQR: 60-84), the 5-year cumulative incidences of late grade 2 or higher GI and GU adverse events (AEs) were 3.3% and 8.1%, respectively. Biochemical recurrences were observed in three patients; no clinical recurrences occurred. The 5-year biochemical recurrence-free, clinical recurrence-free and OS rates were 97.6% (95% CI: 94.9-100.0), 100% and 97.5% (95% CI: 94.8-100.0), respectively. The long-term follow-up results of moderately hypofractionated PBT of 63 Gy (RBE) in 21 fractions confirmed low incidences of late AEs, successfully meeting the primary endpoint. Furthermore, the low incidence of tumor recurrence supports the overall safety and feasibility of this fractionation schedule.
| Reference Key |
openalex_W7170169645
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | Takashi Iizumi, Hitoshi Ishikawa, Yuta Sekino, Motohiro Murakami, Kéiichi Tanaka, Daichi Takizawa, Hirokazu Makishima, Yutaro Mori, Satoshi Kamizawa, Masashi Mizumoto, Toshiyuki Okumura, Hiroyoshi Suzuki, Hiroyuki Nishiyama, Hideyuki Sakurai |
| Journal | journal of radiation research |
| Year | 2026 |
| DOI |
10.1093/jrr/rrag051
|
| URL | |
| Keywords | Keywords not found |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.